Welcome to our dedicated page for Marker Therapeut SEC filings (Ticker: MRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Early-stage cancer innovators like Marker Therapeutics file documents packed with clinical data, grant milestones, and dilution risks—details buried in pages of biotech jargon that can overwhelm even seasoned analysts. Finding Phase 2 trial updates or cash-runway disclosures inside a 10-Q is time-consuming, and tracking when executives buy shares demands constant Form 4 monitoring.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn every “Marker Therapeutics annual report 10-K simplified” or “Marker Therapeutics quarterly earnings report 10-Q filing” into an executive digest you can read in minutes. Real-time alerts flag each “Marker Therapeutics Form 4 insider transactions real-time,” while interactive dashboards explain “Marker Therapeutics 8-K material events explained” the moment they hit EDGAR. You’ll also find:
- Side-by-side R&D spend trends pulled from successive 10-Qs
- Instant highlights of “Marker Therapeutics proxy statement executive compensation”
- One-click access to every “Marker Therapeutics insider trading Form 4 transactions” filed
Whether you’re gauging management confidence through “Marker Therapeutics executive stock transactions Form 4,” or need a quick “Marker Therapeutics earnings report filing analysis” before a call, our expert layer keeps you focused on decisions, not document hunting. Start understanding Marker Therapeutics SEC documents with AI today and follow the science—and the numbers—with confidence.
Marker Therapeutics, Inc. (Nasdaq: MRKR) filed Prospectus Supplement No. 2 to its November 2018 resale registration statement. The sole purpose is to update the “Selling Stockholders” table after John R. Wilson transferred his holdings to the John R. Wilson Revocable Trust U/A DTD 08/03/2017, for which he is sole trustee. The trust now appears as a substitute selling stockholder.
- Shares affected: 781,200 common shares (post-1:10 reverse split) are beneficially owned; up to 606,078 shares (≈0.54 m) are registered for resale; 175,122 shares would remain if the entire allotment is sold.
- Ownership impact: The trust currently controls 1.5 % of MRKR’s 11,314,835 outstanding shares (as of 30 Jun 2025). Percentage falls to ~0.2 % post-sale.
- Capital effects: These are already-issued shares—no new dilution to existing shareholders. However, resale could increase float and near-term supply.
- Price reference: Last reported price on 4 Aug 2025 was $1.24.
- Governance note: Mr. Wilson, a former director, resigned 24 Jan 2025; disclosure aligns holdings with current status.
All other terms, risk factors and the plan of distribution in the original prospectus remain unchanged.